Abstract
BackgroundAdequate surveillance of HIV drug resistance prevalence is challenged by heterogenous and inadequate data reporting. To address this issue, we recently published reporting guidance documentation for studies of HIV drug resistance prevalence and incidence.ObjectivesIn this study, we describe the methods used to develop this reporting guidance.DesignWe used a mixed-methods sequential explanatory design involving authors and users of studies of HIV drug resistance prevalence. In the quantitative phase, we conducted a cross-sectional electronic survey (n=51). Survey participants rated various reporting items on whether they are essential to report. Validity ratios were computed to determine the items to discuss in the qualitative phase. In the qualitative phase, two focus group discussions (n=9 in total) discussed this draft item checklist, providing a justification and examples for each item. We conducted a descriptive qualitative analysis of the group discussions to identify emergent themes regarding the qualities of an essential reporting item.ResultsWe identified 38 potential reporting items that better characterise the study participants, improve the interpretability of study results and clarify the methods used for HIV resistance testing. These items were synthesised to create the reporting item checklist. Qualitative insights formed the basis of the explanation, elaboration, and rationale components of the guidance document.ConclusionsWe generated a list of reporting items for studies on the incidence or prevalence of HIV drug resistance along with an explanation of why researchers believe these items are important. Mixed methods allowed for the simultaneous generation and integration of the item list and qualitative insights. The integrated findings were then further developed to become the subsequently published reporting guidance.
Reference32 articles.
1. WHO . HIV drug resistance: fact sheets. 2020. Available: https://www.who.int/news-room/fact-sheets/detail/hiv-drug-resistance [Accessed 22 Oct 2021].
2. WHO . HIV drug resistance strategy; 2021 update: technical document. 2021.
3. Guidelines are needed for studies of pre-treatment HIV drug resistance: a methodological study;Mbuagbaw;BMC Med Res Methodol,2021
4. Guidance for developers of health research reporting guidelines;Moher;PLoS Med,2010
5. Reporting research results: a moral obligation for all researchers;Moher;Can J Anesth/J Can Anesth,2007